MET
10 drugsMesenchymal-Epithelial Transition Factor
Predictive biomarker for patient selection in 15 indications
Understanding MET
What it means: MET alterations include amplification, exon 14 skipping mutations, and overexpression. Drives cancer growth and metastasis.
Why it matters: MET inhibitors (capmatinib, tepotinib) show high response rates in MET exon 14 skipping mutations.
Testing: Tested via NGS for mutations, FISH for amplification, IHC for overexpression. Liquid biopsy can detect MET alterations.
10
Approved Drugs
15
Indications
8
Companies
MET is a precision-medicine biomarker linked to 10 FDA-approved targeted drugs from 8 companies, spanning 15 indications including Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Advanced renal cell carcinoma. Explore the targeted therapies, indications, testing methods, and companies developing MET drugs below.
Search MET Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting MET
| Drug | Company | Therapeutic Area |
|---|---|---|
| CABOMETYX | EXELIXIS | Oncology |
| COMETRIQ | EXELIXIS | Oncology |
| EMRELIS | AbbVie | Oncology |
| ENSACOVE | XCOVERY | Oncology |
| RESNIBEN | AZURITY | Oncology |
| RYBREVANT | Johnson & Johnson | Oncology |
| RYBREVANT FASPRO | Johnson & Johnson | Oncology |
| TABRECTA | Novartis | Oncology |
| TEPMETKO | EMD SERONO INC | Oncology |
| XALKORI | PF PRISM CV | Oncology |
MET Indications
Non-Small Cell Lung Cancer Medullary Thyroid Cancer Advanced renal cell carcinoma Hepatocellular carcinoma previously treated with sorafenib Locally advanced or metastatic differentiated thyroid cancer Well-differentiated pancreatic neuroendocrine tumors Well-differentiated extra-pancreatic neuroendocrine tumors Metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. Anaplastic Large Cell Lymphoma Inflammatory Myofibroblastic Tumor First-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations (in combination with lazertinib) Locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations that has progressed on or after treatment with an EGFR tyrosine kinase inhibitor (in combination with carboplatin and pemetrexed) First-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations (in combination with carboplatin and pemetrexed) Locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations that has progressed on or after platinum-based chemotherapy (as a single agent) Metastatic non-small cell lung cancer (NSCLC) with a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping